Postoperative pain following neurosurgical craniotomy
Conditions
Interventions
Patients in Group A were administered intravenous hydromorphone hydrochloride at a dose of 0.02 mg/kg
:Each group of subjects received intravenous injection of 0.02 mg/kg of hydromorphone hydrochloride for Group A patients.
Patients in Group B were administered intravenous hydromorphone hydrochloride at a dose of 0.04 mg/kg
:0.04 mg/kg of hydromorphone hydrochloride for Group B patients
Patients in Group C were administered intravenous sufentanil at a dose of 0.3 ug/kg
:0.3 ug/kg of sufentanil for Group C patients, respectively, 30 minutes before the end of surgery.
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.ASA I-III, aged 18-65 years, with a BMI of 18kg/m2 to 30kg/m^2; 2.Patients who are scheduled to undergo neurosurgical craniotomy under general anesthesia; 3.After gaining a full understanding of the research content, all patients expressed their willingness to participate and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Previously had mental illness, severe traumatic brain injury, and central nervous system complications; 2. Accompanied by a history of severe cardiovascular diseases (such as ischemic heart disease, pulmonary heart disease, etc.) and severe abnormalities in liver and kidney function; 3. Individuals who are allergic or tolerant to hydromorphone hydrochloride and its components; 4. Individuals with alcohol and/or drug abuse; 5. Individuals with visual or auditory impairments, unable to communicate, or with incomplete information.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Ramsay score; | — |
Countries
China
Contacts
Public ContactLi Yu
West China Hospital, Sichuan University
Outcome results
None listed